Entering text into the input field will update the search result below

Ophthotech completes patient recruitment for its Phase 2b clinical trial of Zimura

Oct. 04, 2018 8:42 AM ETIVERIC bio, Inc. (ISEE) StockBy: SA News Team
  • Ophthotech Corporation (OPHT) completes patient recruitment for its Phase 2b clinical trial of Zimura (avacincaptad pegol), the C5 inhibitor, monotherapy in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD).
  • A total of 286 patients have been enrolled into this trial. The study is designed to assess the safety and efficacy of various Zimura dosing regimens over 12 months. Initial top-line data from this study is expected in Q4 2019.
  • The Company also expects top-line data for its open-label Phase 2a clinical trial of Zimura combination therapy with Lucentis (ranibizumab) 0.5 mg in treatment-naïve patients with wet AMD before the end of 2018.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
ISEE--
IVERIC bio, Inc.